As demonstrated in 2 double-blind, randomized, controlled studies of 2813 patients with moderate to severe acne:
Patients reported significant improvement as soon as 2 weeks
Significantly more patients treated with Acanya® Gel considered their acne cleared or almost cleared compared with the individual active treatment arms or vehicle at week 12
Optimized formulation designed to encourage adherence to therapy
Convenient once-daily therapy
Can be used under makeup and sunscreen
No alcohol, fragrance, surfactants, parabens, or preservatives
Favorable tolerability profile
In 773 patients treated with Acanya Gel in pivotal studies:
No patients using Acanya Gel discontinued treatment due to erythema, scaling, burning, stinging, or itching
Application-site reactions in the Acanya Gel group were rare (0.1%)
Percentage of patients with cutaneous symptoms: Combined results from the 2 phase 3 trials (N=773)
Indication and Important Safety Information: Acanya Gel is indicated for the topical treatment of acne vulgaris in patients 12 years of age or older. In controlled clinical trials, the following application-site adverse reactions occurred in less than 0.2% of patients treated with Acanya Gel: application-site pain (0.1%), application-site exfoliation (0.1%), and application-site irritation (0.1%). Of the patients who experienced cutaneous symptoms of erythema, scaling, itching, burning, and/or stinging, regardless of the relationship to therapy, the majority of cases were mild to moderate in severity, occurred early in treatment, and decreased thereafter. Acanya Gel is contraindicated in patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis. Diarrhea, bloody diarrhea, and colitis have been reported with the use of topical clindamycin. Discontinuation is recommended if significant diarrhea develops. Patients are advised to avoid applying in mouth, eyes, or nose, or on lips, and to minimize sun exposure following the application of Acanya Gel.
